A Multicenter, Open-label, Non-randomized, Single-arm Phase 1/2 Study of Autologous Nano CD5-CAR T Cells for the Treatment of Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma

NCT07678307 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

T-Cell Acute Lymphoblastic Leukemia
T-Lymphoblastic Lymphoma
Relapsed/Refractory Hematologic Malignancies

Interventions

BIOLOGICAL: Autologous nano CD5-CAR T Cells

Sponsor

Institute of Hematology & Blood Diseases Hospital, China